文献速递心脑血管急症消化、代谢与肾脏急症

依洛尤单抗用于无心肌梗死或卒中病史的患者

Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
PubMed 文献 · N Engl J Med · 2025-11-08
一句话结论在动脉粥样硬化或糖尿病且无心肌梗死或卒中病史、LDL-C≥90 mg/dl的患者中,依洛尤单抗140 mg每2周皮下注射较安慰剂降低3点MACE风险(HR 0.75)。

VESALIUS-CV是一项国际、双盲、随机、安慰剂对照试验,纳入动脉粥样硬化或糖尿病且无既往心肌梗死或卒中、LDL-C至少90 mg/dl的患者12,257例,1:1随机接受依洛尤单抗140 mg每2周或安慰剂。中位随访4.6年,3点MACE在依洛尤单抗组336例(5年Kaplan-Meier估计6.2%)vs 安慰剂组443例(8.0%),HR 0.75(95%CI 0.65-0.86),P<0.001;4点MACE 747例(13.4%)vs 907例(16.2%),HR 0.81(95%CI 0.73-0.89),P<0.001。两组安全性事件发生率未见组间差异证据。

要点

  • 纳入标准:动脉粥样硬化或糖尿病、无既往心肌梗死或卒中、LDL-C至少90 mg/dl,共12,257例随机。
  • 依洛尤单抗140 mg每2周皮下注射,3点MACE 336例(5年KM 6.2%)vs 安慰剂443例(8.0%),HR 0.75(95%CI 0.65-0.86)。
  • 4点MACE 747例(13.4%)vs 907例(16.2%),HR 0.81(95%CI 0.73-0.89)。
  • 中位随访4.6年,两组安全性事件发生率未见组间差异证据。

适用人群与场景

  • 动脉粥样硬化或糖尿病且无既往心肌梗死或卒中、LDL-C至少90 mg/dl的患者。
  • 国际、双盲、随机、安慰剂对照试验人群,中位年龄66岁,43%为女性,93%为白人。

诊断标准与关键阈值

  • LDL-C至少90 mg/dl为纳入阈值。
  • 无既往心肌梗死或卒中为纳入条件。

处置流程与药物剂量

  • 依洛尤单抗140 mg每2周皮下注射(原文未写明给药途径,此处按药物常规途径表述,原文未明确)。
  • 安慰剂对照。

研究设计与关键结果

  • 研究类型:国际、双盲、随机、安慰剂对照试验;样本量12,257例(依洛尤单抗6129例,安慰剂6128例);中位随访4.6年。
  • 3点MACE(冠心病死亡、心肌梗死或缺血性卒中的复合终点):依洛尤单抗组336例(5年Kaplan-Meier估计6.2%)vs 安慰剂组443例(8.0%),HR 0.75(95%CI 0.65-0.86),P<0.001。
  • 4点MACE(3点MACE或缺血驱动的动脉血运重建):依洛尤单抗组747例(5年Kaplan-Meier估计13.4%)vs 安慰剂组907例(16.2%),HR 0.81(95%CI 0.73-0.89),P<0.001。
  • 安全性事件发生率未见组间差异证据。

证据类型、等级与局限

  • 证据类型:随机对照试验(RCT)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于动脉粥样硬化或糖尿病且无既往心肌梗死或卒中、LDL-C至少90 mg/dl的患者,依洛尤单抗140 mg每2周皮下注射较安慰剂降低3点MACE和4点MACE风险。
  • 两组安全性事件发生率未见组间差异证据。

指南或共识出处

  • VESALIUS-CV试验(ClinicalTrials.gov NCT03872401),由Amgen资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, stroke, or symptomatic peripheral artery disease. The effect of evolocumab on the risk of MACE among patients without a previous myocardial infarction or stroke is unknown.

METHODS: We conducted an international, double-blind, randomized, placebo-controlled trial of evolocumab in patients with atherosclerosis or diabetes and without a previous myocardial infarction or stroke who had a low-density lipoprotein cholesterol level of at least 90 mg per deciliter. Patients were randomly assigned in a 1:1 ratio to receive evolocumab at a dose of 140 mg every 2 weeks or placebo. The two primary end points were a composite of death from coronary heart disease, myocardial infarction, or ischemic stroke (3-point MACE) and a composite of 3-point MACE or ischemia-driven arterial revascularization (4-point MACE).

RESULTS: A total of 12,257 patients were randomly assigned to receive evolocumab (6129 patients) or placebo (6128) and were included in the efficacy analyses. The median age of the patients was 66 years, 43% were women, and 93% were White. The median follow-up was 4.6 years. A 3-point MACE event occurred in 336 patients (5-year Kaplan-Meier estimate, 6.2%) in the evolocumab group, as compared with 443 (8.0%) in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.65 to 0.86; P<0.001). A 4-point MACE event occurred in 747 patients (5-year Kaplan-Meier estimate, 13.4%) in the evolocumab group, as compared with 907 (16.2%) in the placebo group (hazard ratio, 0.81; 95% CI, 0.73 to 0.89; P<0.001). No evidence of a between-group difference was seen in the incidence of safety events.

CONCLUSIONS: PCSK9 inhibition with evolocumab led to a lower risk of first cardiovascular events than placebo among patients with atherosclerosis or diabetes and without a previous myocardial infarction or stroke. (Funded by Amgen; VESALIUS-CV ClinicalTrials.gov number, NCT03872401.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Bohula EA, Marston NA, Bhatia AK, et al. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. N Engl J Med. 2025. PMID: 41211925. doi:10.1056/NEJMoa2514428

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。